Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Roivant Sciences (ROIV) Long-Term Investments (2021 - 2025)

Roivant Sciences (ROIV) has disclosed Long-Term Investments for 5 consecutive years, with $283.8 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Long-Term Investments rose 98.55% year-over-year to $283.8 million, compared with a TTM value of $283.8 million through Jun 2025, up 98.55%, and an annual FY2025 reading of $302.9 million, up 105.35% over the prior year.
  • Long-Term Investments was $283.8 million for Q2 2025 at Roivant Sciences, down from $302.9 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $302.9 million in Q1 2025 and bottomed at $135.9 million in Q4 2023.
  • Average Long-Term Investments over 5 years is $189.6 million, with a median of $175.5 million recorded in 2022.
  • The sharpest move saw Long-Term Investments decreased 28.33% in 2024, then soared 105.35% in 2025.
  • Year by year, Long-Term Investments stood at $215.7 million in 2021, then fell by 20.02% to $172.5 million in 2022, then dropped by 21.2% to $135.9 million in 2023, then increased by 19.92% to $163.0 million in 2024, then skyrocketed by 74.11% to $283.8 million in 2025.
  • Business Quant data shows Long-Term Investments for ROIV at $283.8 million in Q2 2025, $302.9 million in Q1 2025, and $163.0 million in Q4 2024.